BOUTInnovator IBD Breakout Opportunities ETF

Grow my money7y track recordRanked #2,539 of 2,960 in this goal

Tracks the performance of the IBD Breakout Stocks Index before fees and expenses.

By Capital-FORCE ETF · Launched 2018

Annual Cost

0.80%

#4,189 of 5,562 · expensive

Fund Size

$16M

#4,483 of 5,562 · small

Return (1Y)Goal

+36.4%

Track Record

7 years

#1,806 of 5,562 · established

Performance

Total-return NAV · USD

Growth of $10,000

$13,547+35.5%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Alternative

Region

North america

Strategy

Index tracking

Index tracked

IBD Breakout Stocks Index

What it actually holds

By weight

Concentration

Top 10 holdings = 54.9% of fundmoderately concentrated

Mount Vernon Liquid Assets Portfolio, LLC

23.2%

Sandisk Corp/DE

4.3%

LivaNova PLC

3.7%

Bilibili Inc

3.6%

Amentum Holdings Inc

3.6%

Medline Inc

3.4%

Wayfair Inc

3.4%

Legence Corp

3.3%

VSE Corp

3.2%

LB Pharmaceuticals Inc

3.2%

Asset allocation

Stocks

99.6%

Cash

0.4%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

21.8%High

Year-on-year price swings

Max drawdown

-36.8%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.70Decent risk-adjusted returns

Sortino (3Y)

0.97Moderate downside risk

Where to buy

Listing

Exchange: NYSE Arca

Full fund details

Objective: Tracks the performance of the IBD Breakout Stocks Index before fees and expenses.
Strategy: Invests primarily in equity securities that comprise the IBD Breakout Stocks Index, replicating its performance. Concentrates investments in consumer discretionary, industrials, and information technology sectors.
Inception date: September 12, 2018
Fund family: Capital-FORCE ETF